Skip to main content
Silence Therapeutics plc (SLNCF)
OTCMKTS · Delayed Price · Currency is USD
1.590
+0.620 (63.92%)
May 29, 2025, 3:00 PM EDT

Revenue by Product

Fiscal year is January - December.
Fiscal Year
 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2017 - 2019
Period Ending
 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2017 - 2019
Ribonucleic Acid Therapeutics
42.35M
Log In
Log In
Log In
Log In
Upgrade
Ribonucleic Acid Therapeutics Growth
31.12%
Log In
Log In
Log In
Log In
Upgrade
Research Collaboration - Mallinckrodt Plc
-
Log In
Log In
Log In
Log In
Upgrade
Research Collaboration - Mallinckrodt Plc Growth
-
Log In
Log In
Log In
Log In
Upgrade
Research Collaboration - Other
-
Log In
Log In
Log In
Log In
Upgrade
Royalties
-
Log In
Log In
Log In
Log In
Upgrade
Royalties Growth
-
Log In
Log In
Log In
Log In
Upgrade
Research Collaboration - AstraZeneca
-
Log In
Log In
Log In
Log In
Upgrade

Revenue by Geography

Fiscal year is January - December.
Fiscal Year
 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2017 - 2019
Period Ending
 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2017 - 2019
United Kingdom
42.21M
Log In
Log In
Log In
Log In
Upgrade
United Kingdom Growth
33.68%
Log In
Log In
Log In
Log In
Upgrade
Germany
140.99K
Log In
Log In
Log In
Log In
Upgrade
Germany Growth
-80.54%
Log In
Log In
Log In
Log In
Upgrade